Literature DB >> 22008306

Selenium inhibits migration of murine melanoma cells via down-modulation of IL-18 expression.

Hyunkeun Song1, Jiyoung Kim, Hyun-Kyung Lee, Hyun-jin Park, Joohyung Nam, Ga Bin Park, Yeong Seok Kim, DaeHo Cho, Dae Young Hur.   

Abstract

Melanoma is an aggressive form of skin cancer due to its rapid metastasis. Recently, several studies have reported that selenium can prevent metastasis of melanoma cells, but the mechanism of this anti-metastatic ability is not fully understood. In this study, we investigated the effect of selenium on cell migration in melanoma and on tumor metastasis in mice. Interestingly, tumor metastasis was suppressed by selenium in a mouse model. Cell migration was measured by a wound-healing assay using selenium-treated melanoma cells. Treatment with a non-cytotoxic concentration of selenium suppressed migration of melanoma cells in a dose-dependent manner. In addition, we found decreased HIF-1α and VEGF expression in selenium-treated melanoma cells as compared to non-treated control cells. Mechanistically, our studies show that selenium inhibits IL-18 gene expression in a dose-dependent manner. IL-18 protein level was suppressed by treatment with selenium. The wound-healing assay revealed that the anti-metastatic effect of selenium was abrogated by treatment with exogenous IL-18. These results suggest that selenium might be a potent inhibitor of the metastatic capacity of melanoma cells, via down-modulation of IL-18 expression.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008306     DOI: 10.1016/j.intimp.2011.10.002

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  10 in total

Review 1.  Selenoproteins and Metastasis.

Authors:  Michael P Marciel; Peter R Hoffmann
Journal:  Adv Cancer Res       Date:  2017-09-01       Impact factor: 6.242

2.  The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.

Authors:  Richard E Kast
Journal:  Chin J Cancer       Date:  2015-04-09

3.  Serum selenium and skin diseases among Nigerians with human immunodeficiency virus/acquired immune deficiency syndrome.

Authors:  Adeolu Oladayo Akinboro; David Ayodele Mejiuni; Olaniyi Onayemi; Olugbenga Edward Ayodele; Adeniran Samuel Atiba; Gbenga Micheal Bamimore
Journal:  HIV AIDS (Auckl)       Date:  2013-08-20

Review 4.  Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and Cancer.

Authors:  Elena Talero; Sofía García-Mauriño; Javier Ávila-Román; Azahara Rodríguez-Luna; Antonio Alcaide; Virginia Motilva
Journal:  Mar Drugs       Date:  2015-09-30       Impact factor: 5.118

5.  Effects of selenium on the survival and invasion of trophoblasts.

Authors:  Jee Yoon Na; Jin Seok; Sohae Park; Jung Seok Kim; Gi Jin Kim
Journal:  Clin Exp Reprod Med       Date:  2018-03-30

6.  Expression of Autoimmunity-Related Genes in Melanoma.

Authors:  Francesca Scatozza; Antonio Facchiano
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

Review 7.  Is selenium a potential treatment for cancer metastasis?

Authors:  Yu-Chi Chen; K Sandeep Prabhu; Andrea M Mastro
Journal:  Nutrients       Date:  2013-04-08       Impact factor: 5.717

8.  Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells.

Authors:  Wouter Hendrickx; Julie Decock; Francis Mulholland; Yongping Bao; Susan Fairweather-Tait
Journal:  Front Oncol       Date:  2013-09-23       Impact factor: 6.244

Review 9.  Putative role of HIF transcriptional activity in melanocytes and melanoma biology.

Authors:  Blazej Zbytek; Danielle L Peacock; Tiffany N Seagroves; Andrzej Slominski
Journal:  Dermatoendocrinol       Date:  2013-04-01

10.  Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia.

Authors:  Indu Sinha; Joshua E Allen; John T Pinto; Raghu Sinha
Journal:  Cancer Med       Date:  2014-02-07       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.